BIRC5 and neoplasm: Dual treatment with a survivin-pulsed DC vaccine and CDDO-Me, compared with vaccination alone, delayed tumor progression and generated synergistic antigen-specific T-cell responses in EL-4 tumor-bearing mice (101).